Oslo, Norway, January 22, 2025 - Lytix Biopharma's licensing partner, Verrica Pharmaceuticals, has presented clinical data on Lytix lead drug candidate, LTX-315, at the 2025 Winter Clinical Dermatology Conference held January 17-19 in Miami, Florida. The results support a potential change in the treatment paradigm for patients with basal cell carcinoma.

The three posters presented by Verrica at the conference highlighted positive clinical data from Part 2 of the Phase 2 study of LTX-315 (named VP-315 by Verrica), a novel oncolytic peptide therapy for the treatment of basal cell carcinoma (BCC). These presentations are important for Lytix, demonstrating the significant progress being made in the development of LTX-315.

BCC is the most common cancer type globally with more than 3.6 million new cases in the US alone, each year.

Highlights from the conference presentations:

Calculated Objective Response Rate (ORR): Verrica reported a calculated ORR of 97% based on post-hoc analysis. This ORR reflects the percentage of study subjects who achieved at least a 30% tumor reduction along with partial or complete response, without disease progression.

Efficacy and safety data: Additional posters featured data on the safety, tolerability, and antitumor efficacy of LTX-315. The study demonstrated a favorable safety profile, with no treatment-related serious adverse events and only mild to moderate treatment-related adverse events.

"We are very pleased with Verrica's presentation of the LTX-315 data at the Winter Clinical Dermatology Conference. These positive results reinforce the potential of LTX-315 to transform the treatment paradigm for basal cell carcinoma and highlight the strength of our oncolytic peptide technology," said Øystein Rekdal, CEO of Lytix Biopharma.

Advancement toward regulatory discussions

Verrica plans to request an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) in the first half of 2025 to determine the next steps for the development of LTX-315 for BCC treatment. Genomic and T-cell immune response data are expected in the first quarter of 2025.

 "The response rate of 97% and the promising safety and efficacy data underline the potential for LTX-315 to provide a much-needed non-surgical treatment option for BCC patients worldwide", adds Rekdal.

Verrica believes that LTX-315 could serve as a potential first-line therapy for both primary and neoadjuvant settings, offering an alternative to invasive surgical treatments. Lytix shares this vision and remains committed to supporting the advancement of LTX-315 as it moves toward Phase III development and broader clinical application.

Read the full press release from Verrica here:

https://verrica.com/press_release/verrica-pharmaceuticals-announces-presentation-of-three-posters-featuring-positive-preliminary-topline-results-of-vp-315-for-the-treatment-of-basal-cell-carcinoma-at-the-2025-winter-clinical-dermatolo/

For any questions, please contact:

Gjest Breistein, CFO

gjest.breistein@lytixbiopharma.com

+47 952 60 512

About Lytix Biopharma

Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma's lead product, LTX-315, is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.